BridgeMD
Combined treatment of intraperitoneal chemotherapy after optimal interval surgery in advanced ovarian cancer. BICOV-1 (Bidirectional Chemotherapy in Ovarian Cancer).
EU CTIS ID: 2022-502691-23-00
What this study is testing
This is a non-commercial clinical study whose main objective is to: Investigate whether the combined administration of HIPEC with cisplatin (100 mg/m2 body surface area) and postoperative bidirectional chemotherapy (intraperitoneal and systemic) after cytoreduction is feasible, effective and safe in patients with IIIB-C/IV ovarian cancer treated with neoadjuvant systemic chemotherapy: The safety of the combined treatment will be evaluated by collecting the complications and adverse effects that are generated in the study patients, which will be compared to the morbidity and mortality described in the scientific literature. Efficacy will be assessed in terms of overall survival and survival disease free at 1, 3 and 5 years. This overall survival will be defined as the interval of time elapsed from the surgical intervention to the death of the patient. The disease-free interval is defined as the time elapsed from surgery to occurrence of disease recurrence. For this, the study will take into account criteria of recurrence currently accepted. These include an elevation of CA125 >70 U/mL if after treatment it was <35U/mL, or an elevation to twice the lowest value obtained with treatment if CA125 did not normalize after treatment. The definitive diagnosis of recurrence must be accompanied either by the appearance of new lesions in studies of imaging or pathological confirmation.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Women between 18-70 years of age with a proven histological diagnosis of FIGO stage IIIB-C/IV epithelial ovarian cancer (high-grade serous epithelial carcinoma).
- CC0 complete cytoreduction without digestive anastomosis.
- Patients who have signed the written informed consent (IC).
- Absence of extraperitoneal disease.
- Adequate functional status: Karnofsky index >70 or Performance status ≤ 2
- Correct liver function, defined as bilirubin <0 1.5 times the upper limit of normal (ULN), aspartate amino transferase and alanine amino transferase ≤ 2.5 times ULN, and alkaline phosphate ≤ 3 times ULN
You likely can't join if
- Disease progression after initiation of systemic neoadjuvant chemotherapy.
- Extraperitoneal disease (including retroperitoneal nodal metastases) at reassessment after systemic neoadjuvant therapy.
- Impossibility of achieving complete cytoreduction (CC-0).
- Active infection of any origin.
- Allogeneic transplant, or prior bone marrow transplant, or high-dose chemotherapy with bone marrow or stem cell rescue.
- Participation in a clinical trial with an investigational drug in the last 30 days.
See the full eligibility criteria
- Women between 18-70 years of age with a proven histological diagnosis of FIGO stage IIIB-C/IV epithelial ovarian cancer (high-grade serous epithelial carcinoma).
- CC0 complete cytoreduction without digestive anastomosis.
- Patients who have signed the written informed consent (IC).
- Absence of extraperitoneal disease.
- Adequate functional status: Karnofsky index >70 or Performance status ≤ 2
- Correct liver function, defined as bilirubin <0 1.5 times the upper limit of normal (ULN), aspartate amino transferase and alanine amino transferase ≤ 2.5 times ULN, and alkaline phosphate ≤ 3 times ULN
- Correct renal function, defined as serum creatinine ≤ 1.5 times ULN
- Acceptable bone marrow function defined as neutrophils >1.5 x 106 l-1, hemoglobin > 10 g/dl-1 and platelets >100.0 x 109 l-1
- Absence of cardiac, pulmonary, hepatic, renal, or neurological disease that contraindicates major surgery.
- Negative result in serum and urine pregnancy test for women of childbearing age at screening visit.
- Administration of neoadjuvant chemotherapy with a total of 3 systemic cycles.
- Disease progression after initiation of systemic neoadjuvant chemotherapy.
- Extraperitoneal disease (including retroperitoneal nodal metastases) at reassessment after systemic neoadjuvant therapy.
- Impossibility of achieving complete cytoreduction (CC-0).
- Active infection of any origin.
- Allogeneic transplant, or prior bone marrow transplant, or high-dose chemotherapy with bone marrow or stem cell rescue.
- Participation in a clinical trial with an investigational drug in the last 30 days.
- Pregnant or lactating women, where pregnancy is defined as the state of a woman after conception and until the end of gestation, confirmed by a positive human chorionic gonadotropin (hCG) test result, or who plans to become pregnant o plan to breast-feed during study treatment or within 30 days of cessation of study drug treatment.
- Patients with a history of allergic reactions or hypersensitivity to drugs chemically related to cisplatin and paclitaxel.
- Failure to sign the written informed consent.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.